Five Prime Therapeutics reported $331.65M in Assets for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Amgen AMGN:US $ 59773M 2766M
Astrazeneca AZN:US $ 73641M 8715M
AstraZeneca AZN:LN 73641M 8715M
Bristol Myers Squibb BMY:US $ 110797M 1638M
Clovis Oncology CLVS:US $ 572.23M 23.39M
Cytokinetics CYTK:US $ 577.06M 43.26M
Daiichi Sankyo 4568:JP Y 2062470M 22708M
Eli Lilly And LLY:US $ 47809M 970.7M
Glaxosmithkline GSK:US $ 77011M 1068M
GlaxoSmithKline GSK:LN 77011M 1068M
Halozyme Therapeutics HALO:US $ 966.58M 386.66M
Immunogen IMGN:US $ 301.45M 44.52M
Ironwood Pharmaceuticals IRWD:US $ 599.34M 40.11M
Karyopharm Therapeutics KPTI:US $ 274.91M 38.14M
Macrogenics MGNX:US $ 425.91M 9.53M
Novartis NVS:US $ 124015M 2263M
Novartis NOVN:VX SF 124015M 2263M
Sangamo Biosciences SGMO:US $ 877.1M 61.46M
Xencor XNCR:US $ 695.6M 2.86M
Ziopharm Oncology ZIOP:US $ 128.47M 17.87M